Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes

被引:6
作者
Lindeblad, Matthew O. [1 ]
Bauer, Kenneth S. [2 ]
Zakharov, Alexander D. [1 ]
Hill, Judith M. [3 ]
Green, Jonathan S. [3 ]
Thomas, Brian F. [3 ]
Schwartz, Arthur [4 ]
Kapetanovic, Izet M. [5 ]
Lyubimov, Alexander [1 ]
机构
[1] Univ Illinois, Dept Pharmacol, Toxicol Res Lab, Chicago, IL 60612 USA
[2] Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, Baltimore, MD 21201 USA
[3] Analyt Chem & Pharmaceut Grp RTI Int, Res Triangle Pk, NC 27709 USA
[4] Temple Univ, Sch Med AS, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA
[5] NCI, Chemoprevent Agent Dev Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA
关键词
DHEA; Fluasterone; Pharmacokinetics; Tissue distribution; Chemoprevention; Beagle dog; METABOLIC SYNDROME; ADIPOSE-TISSUE; DEHYDROEPIANDROSTERONE; MICE; CHEMOPREVENTION; CARCINOGENESIS; INHIBITION; ANALOG; 16-ALPHA-FLUORO-5-ANDROSTEN-17-ONE; SKIN;
D O I
10.1016/j.cbi.2009.10.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of this work was to compare the pharmacokinetics (PK) and tissue distribution of [C-14]fluasterone following intravenous (iv). subcutaneous (sc) and oral (po) administration in male Beagle dogs. The main goal of the investigation was to discover if non-oral routes would alter parameters observed in this study following the administration of [C-14]fluasterone. The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%). Po and sc administration resulted in a similar t(max): however. the observed C-max following sc dosing was less than half of that after oral dosing. The sc route had the greatest overall exposure (AUC(0-infinity)). Tissue distribution analysis 2 In post-intravenous dosing showed that connective tissue (adipose and bone), liver, and skeletal muscle accumulated relatively high levels of fluasterone. The majority of the dose was retained during the first 24h. Elimination of [C-14]fluasterone-derived radioactivity following intravenous dosing resulted in urine and feces containing 7.6% and 28%, respectively, of the total dose over the first 24 h. Elimination of [C-14]fluasterone-derived radioactivity following subcutaneous dosing resulted in 4.6% in urine and 7.8% in feces of the total dose over the first 24 h. Following oral dosing, elimination resulted in 3.8% in urine and 36% in feces over the first 24h. In conclusion, the sc route of administration offers some advantages to po and iv due to the prolonged release and increased retention through 24h. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:317 / 326
页数:10
相关论文
共 23 条
[1]   Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue [J].
Apostolova, G ;
Schweizer, RAS ;
Balazs, Z ;
Kostadinova, RM ;
Odermatt, A .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2005, 288 (05) :E957-E964
[2]   DEHYDROEPIANDROSTERONE ANTAGONIZES THE SUPPRESSIVE EFFECTS OF DEXAMETHASONE ON LYMPHOCYTE-PROLIFERATION [J].
BLAUER, KL ;
POTH, M ;
ROGERS, WM ;
BERNTON, EW .
ENDOCRINOLOGY, 1991, 129 (06) :3174-3179
[3]  
Bosland MC, 2002, EUR J CANCER PREV, V11, pS18
[4]   Physiological parameter values for physiologically based pharmacokinetic models [J].
Brown, RP ;
Delp, MD ;
Lindstedt, SL ;
Rhomberg, LR ;
Beliles, RP .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1997, 13 (04) :407-484
[5]   Identification of [14C]Fluasterone Metabolites in Urine and Feces Collected from Dogs after Subcutaneous and Oral Administration of [14C]Fluasterone [J].
Burgess, Jason P. ;
Green, Jonathan S. ;
Hill, Judith M. ;
Zhan, Qiao ;
Lindeblad, Matthew ;
Lyubimov, Alexander ;
Kapetanovic, Izet M. ;
Schwartz, Arthur ;
Thomas, Brian F. .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (05) :1089-1097
[6]  
CLEARY MP, 1984, J NUTR, V1, P1242
[7]   A good practice guide to the administration of substances and removal of blood, including routes and volumes [J].
Diehl, KH ;
Hull, R ;
Morton, D ;
Pfister, R ;
Rabemampianina, Y ;
Smith, D ;
Vidal, JM ;
van de Vorstenbosch, C .
JOURNAL OF APPLIED TOXICOLOGY, 2001, 21 (01) :15-23
[8]   11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice [J].
Hermanowski-Vosatka, A ;
Balkovec, JM ;
Cheng, K ;
Chen, HY ;
Hernandez, M ;
Koo, GC ;
Le Grand, CB ;
Li, ZH ;
Metzger, JM ;
Mundt, SS ;
Noonan, H ;
Nunes, CN ;
Olson, SH ;
Pikounis, B ;
Ren, N ;
Robertson, N ;
Schaeffer, JM ;
Shah, K ;
Springer, MS ;
Strack, AM ;
Strowski, M ;
Wu, K ;
Wu, TJ ;
Xiao, JY ;
Zhang, BB ;
Wright, SD ;
Thieringer, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :517-527
[9]  
Laatikainen T., 1970, Ann Clin Res., V2, P1
[10]   A transgenic model of visceral obesity and the metabolic syndrome [J].
Masuzaki, H ;
Paterson, J ;
Shinyama, H ;
Morton, NM ;
Mullins, JJ ;
Seckl, JR ;
Flier, JS .
SCIENCE, 2001, 294 (5549) :2166-2170